menu
    • menu

    Company profile for Timberlyne Therapeutics

    NEW Drugs in Dev: 1
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Timberlyne Therapeutics is focused on advancing next-generation therapies for severe diseases. They combine cutting-edge science with patient-centered approaches to deliver impactful treatments. With a team dedicated to innovation and excellence, their goal is to bring transformative solutions to healthcare.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Timberlyne TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    San Diego Area, West Coast
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://timberlyne-tx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/timberlyne-therapeutics/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    BPI Europe

    BPI Europe

    Not Confirmed

    envelop Contact Supplier

    BPI Europe

    Post an Enquiry

    Meeting

    Drugs in Development

    read-more
    read-more
    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Timberlyne Launches With $180M to Develop Anti-CD38 Monoclonal Antibody

    Details:

    Under the terms of the licensing agreement, Timberlyne has obtained exclusive development and commercialization rights to CM313 worldwide outside of greater China.


    Lead Product(s): CM313

    Therapeutic Area: Immunology Brand Name: Undisclosed

    Study Phase: Phase IIProduct Type: Antibody, Unconjugated

    Recipient: Connoya Biomedical Technology

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement January 09, 2025

    blank

    01

    Timberlyne Therapeutics

    U.S.A
    arrow
    Bioprocess International Europe
    Not Confirmed

    Timberlyne Therapeutics

    U.S.A
    arrow
    Bioprocess International Europe
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : CM313

    Therapeutic Area : Immunology

    Highest Development Status : Phase II

    Recipient : Connoya Biomedical Technology

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    Timberlyne Launches With $180M to Develop Anti-CD38 Monoclonal Antibody

    Details : Under the terms of the licensing agreement, Timberlyne has obtained exclusive development and commercialization rights to CM313 worldwide outside of greater China.

    Product Name : Undisclosed

    Product Type : Antibody, Unconjugated

    Upfront Cash : Undisclosed

    January 09, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Timberlyne Raises $180M Series A for CM313, Anti-CD38 Antibody for Unmet Needs

    Details:

    The financing is intended to advance CM313, a potentially best-in-class monoclonal antibody targeting CD38, for immune thrombocytopenic purpura.


    Lead Product(s): CM313

    Therapeutic Area: Immunology Brand Name: Undisclosed

    Study Phase: Phase IIProduct Type: Antibody, Unconjugated

    Sponsor: Abingworth

    Deal Size: $180.0 million Upfront Cash: Undisclosed

    Deal Type: Series A Financing January 09, 2025

    blank

    02

    Timberlyne Therapeutics

    U.S.A
    arrow
    Bioprocess International Europe
    Not Confirmed

    Timberlyne Therapeutics

    U.S.A
    arrow
    Bioprocess International Europe
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : CM313

    Therapeutic Area : Immunology

    Highest Development Status : Phase II

    Partner/Sponsor/Collaborator : Abingworth

    Deal Size : $180.0 million

    Deal Type : Series A Financing

    DEALS_DEV arrow-down

    Timberlyne Raises $180M Series A for CM313, Anti-CD38 Antibody for Unmet Needs

    Details : The financing is intended to advance CM313, a potentially best-in-class monoclonal antibody targeting CD38, for immune thrombocytopenic purpura.

    Product Name : Undisclosed

    Product Type : Antibody, Unconjugated

    Upfront Cash : Undisclosed

    January 09, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search